Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.12
BASI's Cash to Debt is ranked lower than
52% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. BASI: 0.12 )
BASI' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.12

Equity to Asset 0.40
BASI's Equity to Asset is ranked higher than
58% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. BASI: 0.40 )
BASI' s 10-Year Equity to Asset Range
Min: 0.35   Max: 0.83
Current: 0.4

0.35
0.83
Interest Coverage 1.28
BASI's Interest Coverage is ranked lower than
56% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.48 vs. BASI: 1.28 )
BASI' s 10-Year Interest Coverage Range
Min: 0.27   Max: 11
Current: 1.28

0.27
11
F-Score: 6
Z-Score: 0.77
M-Score: -2.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 3.89
BASI's Operating margin (%) is ranked higher than
75% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. BASI: 3.89 )
BASI' s 10-Year Operating margin (%) Range
Min: -20.16   Max: 13.81
Current: 3.89

-20.16
13.81
Net-margin (%) -1.75
BASI's Net-margin (%) is ranked higher than
71% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.44 vs. BASI: -1.75 )
BASI' s 10-Year Net-margin (%) Range
Min: -22.65   Max: 6.99
Current: -1.75

-22.65
6.99
ROE (%) -4.41
BASI's ROE (%) is ranked higher than
69% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.21 vs. BASI: -4.41 )
BASI' s 10-Year ROE (%) Range
Min: -50.76   Max: 10.43
Current: -4.41

-50.76
10.43
ROA (%) -1.68
BASI's ROA (%) is ranked higher than
71% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. BASI: -1.68 )
BASI' s 10-Year ROA (%) Range
Min: -21.54   Max: 6.47
Current: -1.68

-21.54
6.47
ROC (Joel Greenblatt) (%) 5.53
BASI's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. BASI: 5.53 )
BASI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -28.95   Max: 15.89
Current: 5.53

-28.95
15.89
Revenue Growth (%) -23.30
BASI's Revenue Growth (%) is ranked higher than
57% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. BASI: -23.30 )
BASI' s 10-Year Revenue Growth (%) Range
Min: -23.3   Max: 15
Current: -23.3

-23.3
15
EBITDA Growth (%) 75.70
BASI's EBITDA Growth (%) is ranked higher than
98% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. BASI: 75.70 )
BASI' s 10-Year EBITDA Growth (%) Range
Min: -61.2   Max: 119.8
Current: 75.7

-61.2
119.8
» BASI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

BASI Guru Trades in Q3 2013

Jim Simons 21,100 sh (-15.94%)
» More
Q4 2013

BASI Guru Trades in Q4 2013

Jim Simons 16,800 sh (-20.38%)
» More
Q1 2014

BASI Guru Trades in Q1 2014

Jim Simons 12,500 sh (-25.6%)
» More
Q2 2014

BASI Guru Trades in Q2 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BASI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.20
BASI's P/B is ranked higher than
86% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. BASI: 2.20 )
BASI' s 10-Year P/B Range
Min: 0.23   Max: 3.23
Current: 2.2

0.23
3.23
P/S 0.80
BASI's P/S is ranked higher than
94% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.11 vs. BASI: 0.80 )
BASI' s 10-Year P/S Range
Min: 0.1   Max: 1.29
Current: 0.8

0.1
1.29
PFCF 17.80
BASI's PFCF is ranked higher than
64% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BASI: 17.80 )
BASI' s 10-Year PFCF Range
Min: 1.61   Max: 113.8
Current: 17.8

1.61
113.8
EV-to-EBIT 26.93
BASI's EV-to-EBIT is ranked higher than
82% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BASI: 26.93 )
BASI' s 10-Year EV-to-EBIT Range
Min: -269.8   Max: 189.7
Current: 26.93

-269.8
189.7
Current Ratio 0.71
BASI's Current Ratio is ranked lower than
53% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. BASI: 0.71 )
BASI' s 10-Year Current Ratio Range
Min: 0.37   Max: 3.95
Current: 0.71

0.37
3.95
Quick Ratio 0.56
BASI's Quick Ratio is ranked lower than
54% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. BASI: 0.56 )
BASI' s 10-Year Quick Ratio Range
Min: 0.26   Max: 3.05
Current: 0.56

0.26
3.05

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.57
BASI's Price/Tangible Book is ranked higher than
88% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.28 vs. BASI: 2.57 )
BASI' s 10-Year Price/Tangible Book Range
Min: 0.33   Max: 3.34
Current: 2.57

0.33
3.34
Price/DCF (Projected) 1.65
BASI's Price/DCF (Projected) is ranked higher than
92% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BASI: 1.65 )
BASI' s 10-Year Price/DCF (Projected) Range
Min: 0.28   Max: 63
Current: 1.65

0.28
63
Price/Median PS Value 1.44
BASI's Price/Median PS Value is ranked higher than
70% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. BASI: 1.44 )
BASI' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 3.45
Current: 1.44

0.23
3.45
Earnings Yield (Greenblatt) 3.70
BASI's Earnings Yield (Greenblatt) is ranked higher than
82% of the 248 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. BASI: 3.70 )
BASI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 10
Current: 3.7

0.5
10
Forward Rate of Return (Yacktman) 0.59
BASI's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. BASI: 0.59 )
BASI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9.6   Max: 34.5
Current: 0.59

-9.6
34.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:BS5.Germany
Bioanalytical Systems Inc is a corporation organized in Indiana in 1974. The Company is a contract research organization providing drug discovery and development services and analytical instruments. Its clients and partners include pharmaceutical, biotechnology, academic and government organizations. It supports the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates. The Companys principal clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic research from small start-up biotechnology companies to many of the largest global pharmaceutical companies. The drug discovery and development process is heavily regulated by the FDA and its Center for Drug Evaluation and Research. It operates in two business segments contract research services and research products, both of which address the bioanalytical, preclinical, and clinical research needs of drug developers. The contract research services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance and quality control testing. The services provided by its contract research services segment include Product Characterization, Method Development and Validation, Bioanalytical Testing, Stability Testing, In Vivo Pharmacology, and Preclinical and Pathology Services. The products business targets life science research and designs, develops, manufactures and markets Analytical Products, In vivo Sampling Products, Vetronics Products. It promotes its services through concentrated business development efforts, scientist-to-scientist communications and centralized corporate marketing programs. The Company competes with in-house research, development, quality control and other support service departments of pharmaceutical and biotechnology companies. Its competitors include Covance, Inc., Pharmaceutical Product Development, Inc., Charles River Laboratories, Inc., Quintiles Transnational Holdings, Inc. The Company is subject to various regulatory requirements designed to ensure the quality and integrity of its data and products.
» More Articles for BASI

Headlines

Articles On GuruFocus.com
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 09 2011 
Bioanalytical Systems Inc. Reports Operating Results (10-Q/A) May 20 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) May 17 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 16 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-K/A) Feb 10 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Aug 12 2009 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) May 18 2009 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 23 2009 

More From Other Websites
Nasdaq stocks posting largest volume increases Nov 26 2014
3 Diversified Services Stocks Nudging The Industry Higher Oct 20 2014
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Change in Directors or Principal Officers Oct 09 2014
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Change in Directors or Principal Officers Sep 23 2014
BASi Names Connie Dougherty Vice President Business Development Sep 16 2014
BIOANALYTICAL SYSTEMS INC Financials Aug 23 2014
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 14 2014
BIOANALYTICAL SYSTEMS INC Files SEC form 10-Q, Quarterly Report Aug 14 2014
CORRECTING and REPLACING BASi Reports Third Quarter Net Income of $.03 Per Share Aug 14 2014
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jul 02 2014
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 12 2014
BASi Names Jeffrey Potrzebowski CFO and James Bourdage VP Bioanalytical Operations Jun 12 2014
BASi Hosts In Vivo Drug Discovery Workshop at UCLA May 30 2014
Bioanalytical Systems' (BASI) CEO Jackie Lemke on Q2 2014 Results - Earnings Call Transcript May 15 2014
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 15 2014
Bioanalytical Systems reports Q2 EPS ex-items 0c vs. (2c) last year May 15 2014
BASi Reports Second Quarter Results May 15 2014
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Mar 14 2014
Bioanalytical Systems' CEO Discusses F1Q2014 Results - Earnings Call Transcript Feb 13 2014
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK